| Recognition and reporting of suspected adverse drug reactions by surveyed healthcare professionals in Uganda: key determinants R Kiguba, C Karamagi, P Waako, HB Ndagije, SM Bird Bmj open 4 (11), e005869, 2014 | 45 | 2014 |
| Targeted Spontaneous Reporting of suspected renal toxicity in patients undergoing Highly Active Anti-Retroviral Therapy in two public health facilities in Uganda H Ndagije, V Nambasa, E Namagala, H Nassali, D Kajungu, G Sematiko, ... Drug safety 38 (4), 395-408, 2015 | 27 | 2015 |
| Medication error disclosure and attitudes to reporting by healthcare professionals in a sub-Saharan African setting: a survey in Uganda R Kiguba, P Waako, HB Ndagije, C Karamagi Drugs-real world outcomes 2, 273-287, 2015 | 24 | 2015 |
| The burden of adverse drug reactions due to artemisinin-based antimalarial treatment in selected Ugandan health facilities: an active follow-up study HB Ndagije, V Nambasa, L Manirakiza, D Kusemererwa, D Kajungu, ... Drug safety 41, 753-765, 2018 | 21 | 2018 |
| Adverse Drug Reaction Onsets in Uganda’s VigiBase®: Delayed International Visibility, Data Quality and Illustrative Signal Detection Analyses R Kiguba, HB Ndagije, V Nambasa, SM Bird Pharmaceutical Medicine 32, 413-427, 2018 | 20 | 2018 |
| The effect of community dialogues and sensitization on patient reporting of adverse events in rural Uganda: Uncontrolled before-after study HB Ndagije, L Manirakiza, D Kajungu, E Galiwango, D Kusemererwa, ... PloS one 14 (5), e0203721, 2019 | 15 | 2019 |
| Prescription of levofloxacin and moxifloxacin in select hospitals in Uganda: a pilot study to assess guideline concordance V Nambasa, HB Ndagije, A Serwanga, L Manirakiza, J Atuhaire, D Nakitto, ... Antibiotics 9 (8), 439, 2020 | 12 | 2020 |
| Evaluation of the clinical use of ceftriaxone among in-patients in selected health facilities in Uganda P Kutyabami, EI Munanura, R Kalidi, S Balikuna, M Ndagire, B Kaggwa, ... Antibiotics 10 (7), 779, 2021 | 8 | 2021 |
| Facilitators and barriers to uptake of the med safety mobile app for adverse drug reaction reporting by health workers in Uganda: a qualitative study R Kiguba, H Zakumumpa, HB Ndagije, N Mwebaza, R Ssenyonga, ... Drug Safety 46 (6), 565-574, 2023 | 7 | 2023 |
| Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study H Zakumumpa, FE Kitutu, HB Ndagije, NK Diana, JN Ssanyu, R Kiguba BMC Infectious Diseases 21, 1-13, 2021 | 7 | 2021 |
| Drug use evaluation (DUE) of ceftriaxone in mubende regional referral hospital, Uganda: a cross-sectional survey L Manirakiza, V Nambasa, S Nanyonga, A Serwanga, M Alphonsus, ... Journal of Pharmacy and Pharmacology Research 3 (4), 105-115, 2019 | 7 | 2019 |
| The ISoP PatEG-SIG for promoting patient engagement in pharmacovigilance: a change of paradigm is needed MM Younus, M Alkhakany, P Bahri, A Caro, H Rostom, HB Ndagije, ... Drug Safety 46 (7), 619-623, 2023 | 6 | 2023 |
| The challenging times and opportunities for pharmacovigilance in Africa during the COVID-19 pandemic C Ogar, W Mathenge, C Khaemba, H Ndagije Drugs & Therapy Perspectives 36 (8), 351-354, 2020 | 6 | 2020 |
| Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster … R Kiguba, N Mwebaza, R Ssenyonga, HB Ndagije, V Nambasa, ... BMJ open 12 (7), e061725, 2022 | 5 | 2022 |
| Healthcare professionals’ perspective can guide post-marketing surveillance of artemisinin-based combination therapy in Uganda HB Ndagije, R Kiguba, L Manirakiza, E Kirabira, A Sserwanga, L Nabirye, ... Malaria Journal 19, 1-12, 2020 | 5 | 2020 |
| Rare, serious, and comprehensively described suspected adverse drug reactions reported by surveyed healthcare professionals in Uganda R Kiguba, C Karamagi, P Waako, HB Ndagije, SM Bird PloS one 10 (4), e0123974, 2015 | 5 | 2015 |
| Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study H Zakumumpa, R Kiguba, HB Ndagije, G Ategeka, JN Ssanyu, FE Kitutu BMC Infectious Diseases 22 (1), 692, 2022 | 4 | 2022 |
| Pharmacovigilance of suspected or confirmed therapeutic ineffectiveness of artemisinin-based combination therapy: extent, associated factors, challenges and solutions to reporting R Kiguba, HB Ndagije, V Nambasa, L Manirakiza, E Kirabira, A Serwanga, ... Malaria Journal 19, 1-10, 2020 | 4 | 2020 |
| Drug safety in Africa: a review of systems and resources for pharmacovigilance HB Ndagije, D Walusimbi, J Atuhaire, S Ampaire Expert Opinion on Drug Safety 22 (10), 891-895, 2023 | 3 | 2023 |
| Antimicrobial consumption surveillance in Uganda: Results from an analysis of national import data for the human health sector, 2018–2021 M Murungi, HB Ndagije, R Kiggundu, DN Kesi, JP Waswa, K Rajab, ... Journal of Infection and Public Health 16, 45-51, 2023 | 2 | 2023 |
